NONOF - Novo Nordisk GAAP EPS of DKK 4.91 revenue of DKK 65.86B; initiates FY24 outlook January, 31 2024 01:40 AM Novo-Nordisk A/S 2024-01-31 01:40:15 ET More on Novo Nordisk Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Taking Novo Nordisk To The Next Level Suspected fake Ozempic linked to three cases of low blood sugar in U.S.: Reuters For further details see: Novo Nordisk GAAP EPS of DKK 4.91, revenue of DKK 65.86B; initiates FY24 outlook